Stock GENX GENIX PHARMACEUTICALS CORPORATION
Add to a list
To use this feature you must be a member
Log inSign up

Highlights Genix Pharmaceuticals Corporation Toronto S.E.

Equities

GENX

CA0209261019

Delayed Toronto S.E.
Other stock markets
 05:00:00 2021-10-04 pm EDT 		5-day change 1st Jan Change
0.17 CAD -.--% Intraday chart for Genix Pharmaceuticals Corporation -.--% -.--%
Jun. 26 Genix Pharmaceuticals Corporation Reports Earnings Results for the Second Quarter and Six Months Ended April 30, 2024 CI
Mar. 26 Genix Pharmaceuticals Corporation Reports Earnings Results for the First Quarter Ended January 31, 2024 CI

Highlights

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Genix Pharmaceuticals Corporation Reports Earnings Results for the Second Quarter and Six Months Ended April 30, 2024
CI
Genix Pharmaceuticals Corporation Reports Earnings Results for the First Quarter Ended January 31, 2024
CI
Genix Pharmaceuticals Corporation Reports Earnings Results for the Full Year Ended October 31, 2023
CI
Genix Pharmaceuticals Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended July 31, 2023
CI
Genix Pharmaceuticals Corporation Reports Earnings Results for the Second Quarter and Six Months Ended April 30, 2023
CI
Genix Pharmaceuticals Corporation Reports Earnings Results for the Full Year Ended October 31, 2022
CI
Genix Pharmaceuticals Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended July 31, 2022
CI
Genix Pharmaceuticals Corporation Reports Earnings Results for the Second Quarter and Six Months Ended April 30, 2022
CI
Genix Pharmaceuticals Corporation Reports Earnings Results for the First Quarter Ended January 31, 2022
CI
Genix Pharmaceuticals Corporation Reports Earnings Results for the Full Year Ended October 31, 2021
CI
Genix Pharmaceuticals Corporation Reports Earnings Results for the Third Quarter Ended July 31, 2021
CI
Genix Pharmaceuticals Corporation Reports Earnings Results for the Second Quarter Ended April 30, 2021
CI
Genix Pharmaceuticals : Starts Trading on OTCQB Venture Market Exchange
MT
Genix Pharmaceuticals Corporation Enters into Exclusive License and Supply Agreement for First Generic Thyroid Medication
CI
Genix Pharmaceuticals Corporation Prepares to File Abbreviated New Drug Submissions for its First Ten Ophthalmic Drugs with Health Canada
CI
Genix Pharmaceuticals Corporation Reports Earnings Results for the Full Year Ended October 31, 2020
CI
Genix Pharmaceuticals Corporation Reports Earnings Results for the Third Quarter Ended July 31, 2020
CI
Genix Pharmaceuticals Corporation completed the acquisition of global distribution, sales and marketing rights and interest for Flu-X(r) from Canagen Pharmaceuticals Inc.
CI
Genix Pharmaceuticals Corporation Reports Earnings Results for the First Quarter Ended January 31, 2020
CI
Genix Pharmaceuticals Corporation entered into a definitive agreement to acquire global distribution, sales and marketing rights and interest for Flu-X(r) from Canagen Pharmaceuticals Inc. for CAD 0.1 million.
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. GENX Stock
  4. GENX Stock
  5. News Genix Pharmaceuticals Corporation
  6. Highlights